Lv1
40 积分 2022-10-18 加入
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
1个月前
已完结
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations
1个月前
已关闭
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma
1个月前
已完结
Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment
7个月前
已完结
Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia
9个月前
已完结
A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
9个月前
已完结
Dual function of activated PPARγ by ligands on tumor growth and immunotherapy
11个月前
已完结
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes
11个月前
已完结
Development of Potent MALT1 Inhibitors Featuring a Novel “2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one” Scaffold for the Treatment of B Cell Lymphoma
11个月前
已完结
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma
11个月前
已完结
皖公网安备34019202002308
